KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Biomarin Pharmaceutical (BMRN) over the last 17 years, with Q3 2025 value amounting to $113.9 million.

  • Biomarin Pharmaceutical's Change in Accured Expenses fell 681.96% to $113.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.2 million, marking a year-over-year decrease of 7613.7%. This contributed to the annual value of -$32.2 million for FY2024, which is 14682.44% down from last year.
  • Biomarin Pharmaceutical's Change in Accured Expenses amounted to $113.9 million in Q3 2025, which was down 681.96% from $8.2 million recorded in Q2 2025.
  • Biomarin Pharmaceutical's 5-year Change in Accured Expenses high stood at $122.3 million for Q3 2024, and its period low was -$100.3 million during Q4 2024.
  • Its 5-year average for Change in Accured Expenses is $12.1 million, with a median of $8.2 million in 2025.
  • Per our database at Business Quant, Biomarin Pharmaceutical's Change in Accured Expenses surged by 360779.22% in 2021 and then crashed by 90079.07% in 2024.
  • Quarter analysis of 5 years shows Biomarin Pharmaceutical's Change in Accured Expenses stood at $22.8 million in 2021, then surged by 172.9% to $62.3 million in 2022, then plummeted by 79.89% to $12.5 million in 2023, then plummeted by 900.79% to -$100.3 million in 2024, then skyrocketed by 213.65% to $113.9 million in 2025.
  • Its last three reported values are $113.9 million in Q3 2025, $8.2 million for Q2 2025, and -$2.7 million during Q1 2025.